Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Signifies the FDA’s recognition of the Company’s novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis


Opens an accelerated path...

Related Keywords

United States ,American ,Frank Karbe ,Naim Alkhouri ,Drug Administration ,Nasdaq ,Steatotic Liver Program At Arizona Health ,Exchange Commission ,Better Therapeutics Inc ,Better Therapeutics ,Breakthrough Device Designation ,Cognitive Behavioral Therapy ,Gastro Hep ,Chief Executive Officer ,Steatotic Liver Program ,Arizona Liver Health ,Principal Investigator ,Livvita Liver ,Better Therapeutic ,Markets ,